0001209191-23-058574.txt : 20231213 0001209191-23-058574.hdr.sgml : 20231213 20231213213213 ACCESSION NUMBER: 0001209191-23-058574 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231002 FILED AS OF DATE: 20231213 DATE AS OF CHANGE: 20231213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mackaness James H CENTRAL INDEX KEY: 0001422484 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 231485417 MAIL ADDRESS: STREET 1: 1212 TERRA BELLA AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 203 REDWOOD SHORES PARKWAY STREET 2: SUITE 500 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 203 REDWOOD SHORES PARKWAY STREET 2: SUITE 500 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-02 0 0001484565 SOLENO THERAPEUTICS INC SLNO 0001422484 Mackaness James H 203 REDWOOD SHORES PKWY, STE 500 REDWOOD CITY CA 94065 0 1 0 0 Chief Financial Officer 0 Common Stock 2023-10-02 4 M 0 2666 4.50 A 36236 D Common Stock 2023-10-02 4 M 0 2143 1.75 A 38379 D Common Stock 2023-10-02 4 M 0 3500 2.50 A 41879 D Warrants (right to buy) 4.50 2023-10-02 4 M 0 2666 0.00 D 2022-03-31 2027-03-31 Common Stock 2666 0 D Warrants (right to buy) 1.75 2023-10-02 4 M 0 2143 0.4425 D 2023-05-08 Common Stock 2143 0 D Warrants (right to buy) 2.50 2023-10-02 4 M 0 3500 0.4425 D 2023-05-08 Common Stock 3500 0 D The number of shares reported as beneficially owned following the reported transaction is as of October 2, 2023. The Warrants expire upon the earlier of (i) 30 days following announcement of positive top-line data from the randomized withdrawal period of Study C602, an open-label extension study pertaining to Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS), or (ii) November 8, 2026. The Warrants expire upon the earlier of (i) 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS or (ii) November 8, 2026. /s/ James Mackaness 2023-12-13